This activity does not offer CE. Peter Marks, M.D., Ph.D., Director of the Center for Biologics Evaluation and Research (CBER) at the FDA, will provide insight into the first few months of vaccine rollout, and what we have learned about the vaccine candidates, and the SARS-CoV-2 variants.
COVID-19
infectious diseases